Aptevo Therapeutics Inc. (APVO) stock
APVONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.46−0.09 (-15.97%)
Close on Nov 17, 2026Market cap $830.71KP/E –Yield –
Aptevo Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Aptevo Therapeutics's total assets was $14.52M at Jun 30, 2026. For fiscal 2025 it was $27.19M, up 74.4% from the year before. Over ten years it grew -14.3% a year on average. The highest annual figure on record is $127.77M in fiscal 2015.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.19M | +74.4% |
| FY2024 | Dec 31, 2024 | $15.59M | -37.2% |
| FY2023 | Dec 31, 2023 | $24.84M | -27.4% |
| FY2022 | Dec 31, 2022 | $34.22M | -39.6% |
| FY2021 | Dec 31, 2021 | $56.60M | +5.7% |
| FY2020 | Dec 31, 2020 | $53.55M | +0.3% |
| FY2019 | Dec 31, 2019 | $53.41M | -20.9% |
| FY2018 | Dec 31, 2018 | $67.49M | -42.3% |
| FY2017 | Dec 31, 2017 | $117.01M | +27.4% |
| FY2016 | Dec 31, 2016 | $91.86M | -28.1% |
| FY2015 | Dec 31, 2015 | $127.77M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $14.52M | -7.1% |
| Q1 FY2026 | Mar 31, 2026 | $19.90M | +138.6% |
| Q4 FY2025 | Dec 31, 2025 | $27.19M | +74.4% |
| Q3 FY2025 | Sep 30, 2025 | $27.00M | +78.2% |
| Q2 FY2025 | Jun 30, 2025 | $15.62M | +4.7% |
| Q1 FY2025 | Mar 31, 2025 | $8.34M | -52.7% |
| Q4 FY2024 | Dec 31, 2024 | $15.59M | -37.2% |
| Q3 FY2024 | Sep 30, 2024 | $15.15M | -44.2% |
| Q2 FY2024 | Jun 30, 2024 | $14.92M | -48.4% |
| Q1 FY2024 | Mar 31, 2024 | $17.63M | -49.6% |
| Q4 FY2023 | Dec 31, 2023 | $24.84M | -27.4% |
| Q3 FY2023 | Sep 30, 2023 | $27.13M | -14.4% |
| Q2 FY2023 | Jun 30, 2023 | $28.91M | -25.5% |
| Q1 FY2023 | Mar 31, 2023 | $34.97M | -22.6% |
| Q4 FY2022 | Dec 31, 2022 | $34.22M | -39.6% |
| Q3 FY2022 | Sep 30, 2022 | $31.70M | -50.5% |
| Q2 FY2022 | Jun 30, 2022 | $38.80M | -45.7% |
| Q1 FY2022 | Mar 31, 2022 | $45.18M | -34.3% |
| Q4 FY2021 | Dec 31, 2021 | $56.60M | +5.7% |
| Q3 FY2021 | Sep 30, 2021 | $64.01M | +71.0% |
| Q2 FY2021 | Jun 30, 2021 | $71.47M | +286.2% |
| Q1 FY2021 | Mar 31, 2021 | $68.75M | +172.4% |
| Q4 FY2020 | Dec 31, 2020 | $53.55M | +0.3% |
| Q3 FY2020 | Sep 30, 2020 | $37.42M | -38.2% |
| Q2 FY2020 | Jun 30, 2020 | $18.51M | -72.0% |
| Q1 FY2020 | Mar 31, 2020 | $25.24M | -68.8% |
| Q4 FY2019 | Dec 31, 2019 | $53.41M | -20.9% |
| Q3 FY2019 | Sep 30, 2019 | $60.56M | -23.3% |
| Q2 FY2019 | Jun 30, 2019 | $66.13M | -26.5% |
| Q1 FY2019 | Mar 31, 2019 | $80.84M | -19.3% |
| Q4 FY2018 | Dec 31, 2018 | $67.49M | -42.3% |
| Q3 FY2018 | Sep 30, 2018 | $78.93M | -39.8% |
| Q2 FY2018 | Jun 30, 2018 | $90.00M | +3.6% |
| Q1 FY2018 | Mar 31, 2018 | $100.21M | +2.5% |
| Q4 FY2017 | Dec 31, 2017 | $117.01M | +27.4% |
| Q3 FY2017 | Sep 30, 2017 | $131.02M | +30.2% |
| Q2 FY2017 | Jun 30, 2017 | $86.89M | – |
| Q1 FY2017 | Mar 31, 2017 | $97.79M | – |
| Q4 FY2016 | Dec 31, 2016 | $91.86M | – |
| Q3 FY2016 | Sep 30, 2016 | $100.62M | – |
See a number that looks wrong?